SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing a sharp sell-off driven by a confluence of negative sentiment, including a federal jury finding that Elon Musk defrauded Twitter shareholders and concerns regarding broader macroeconomic instability. The community is deeply divided, with bears pointing to falling delivery numbers and operational scrutiny as evidence of a structural decline, while loyal bulls continue to highlight upcoming projects like TeraFab and the potential for a rebound as reasons to maintain their positions.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as investors debate the long-term potential of the project, with many in the community expressing unwavering patience for a future breakout despite current price volatility. Supporters are actively highlighting the project's utility and health-focused mechanics, often drawing comparisons to historical market recoveries to justify their continued accumulation.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors capitalize on its recent NYSE listing, which provides rare public market access to high-profile private AI and tech companies like Anthropic, OpenAI, and SpaceX. While the community is actively debating the significant premium over the fund's net asset value and the impact of a six-month lockup on available float, many are focused on the stock's high volatility and potential for momentum-driven price swings.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is currently trending due to a major data breach involving approximately 33 million accounts, sparking intense regulatory scrutiny, a nationwide boycott in South Korea, and a significant leadership shake-up. Investors are actively debating the potential for long-term recovery against the backdrop of mounting legal liabilities, government investigations, and consumer backlash that threatens to disrupt the company's core market.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone shares are under pressure as investors react to mixed signals regarding private credit exposure and shifting regulatory landscapes, despite the firm reporting a significant earnings beat and record assets under management. Market participants are actively debating whether the recent dip represents a buying opportunity in a high-growth financial leader or a warning sign of broader systemic risks within the alternative asset sector.

KKR & Co., Inc. operates as an investment firm. It offers alternative asset management as well as capital markets and insurance solutions. The firm's business segments include Asset Management and Insurance Business. The Asset Management segment engages in providing private equity, real assets, credit and liquid strategies, capital markets, and principal activities. The Insurance Business segment offers retirement, life insurance and reinsurance solutions to clients across individual and institutional markets. The company was founded by Henry Kravis, George R. Roberts, and Jerome Kholberg on May 1, 1976 and is headquartered in New York, NY.

KKR & Co. Inc

KKR & Co. Inc.

KKR is actively being discussed as a major player in the private credit and infrastructure space, with investors noting a positive trend following record fee-related earnings and significant capital raising milestones. The community remains focused on KKR's ongoing pivot toward permanent capital and wealth management, viewing the stock as a compelling long-term play despite broader market volatility and questions surrounding the liquidity of private markets.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is currently capturing significant market interest as it benefits from surging demand for AI-driven chip fabrication equipment, with community members actively monitoring its strong relative strength against industry peers. Investors are closely tracking upcoming earnings while debating the stock's valuation and potential upside against the backdrop of broader semiconductor sector consolidation.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors focus on its integration into the AI-native economy, with community discussion highlighting its role in chain abstraction, privacy-focused protocols, and recent infrastructure developments. Many are closely watching the balance between retail accumulation and institutional activity while expressing optimism about its long-term utility in the decentralized AI landscape.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing increased investor attention as the community anticipates strategic government contracts and potential national security roles for its domestic pharmaceutical manufacturing capabilities. Shareholders are actively monitoring executive activity and long-term asset value, fueling optimism that the companys ongoing operational turnaround and pivot toward critical supplies could serve as a significant catalyst for growth.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as community discussions center on the Supreme Court's potential involvement in its patent infringement case against Hikma, following the Solicitor General's filing. Investors are also closely monitoring the upcoming EMT2 trial results and potential M&A activity as the company continues its restructuring and cost-cutting initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut shares of Tenaya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)

Chardan Capital reiterated a "buy" rating and set a $8.00 price target on shares of Tenaya Therapeutics in a research report on Thursday...

Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) released its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates...

Lifesci Capital Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Strong-Buy

Lifesci Capital raised shares of Tenaya Therapeutics to a "strong-buy" rating in a report on Thursday...

<ul class="summary-bullets"><li>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam.</li><li>Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.</li></ul> Shares of Tenaya Therapeutics, Inc. (TNYA) pulled back after hours after a significant rally during the regular session on Thursday after the company said that it has entered into a research collaboration deal with Alnylam Pharmaceuticals (ALNY) to potentially develop drugs for cardiovascular disease.TNYA shares pulled back 5% in extended hours of trading after closing up 41% in the regular session.<h2 class="st-heading-2">Deal For Heart Drugs</h2>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam if all the targets lead to approved therapies for cardiovascular disease. Tenaya will receive up to $10 million in the form of an upfront payment, the company said.“By combining our modality agnostic target identification and validation capabilities with Alnylam’s leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease,” Tenaya CEO Faraz Ali said.Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNYA stock rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user said that they are awaiting positive data for Tenaya’s TN401 this year with “no curative competition.” TN-401 is a gene therapy for a heart condition called PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).<stembedurl>https://www.stocktwits.com/Raumerica/message/646689743</stembedurl>Another said that the best part about the deal is that Tenaya will just be researching fifteen additional targets for future commercialisation while still owning all of its own drugs.<stembedurl>https://www.stocktwits.com/Raumerica/message/646703938</stembedurl><a href="https://stocktwits.com/symbol/TNYA">TNYA stock</a> has gained 78% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/owlet-stock-is-down-26-percent-after-hours-after-it-reports-q4-2025-earnings/cZdX4n1RI36">Owlet Stock Is Down 26% After Hours – How Did The Company’s Q4 Results Fare?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 

Equity

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 


Tenaya Therapeutics Stock Jumps After New Alnylam Deal

Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.read more...

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Monday

Tenaya Therapeutics (NASDAQ:TNYA) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...

Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Group Gp Lp Column III Sells 658,440 Shares

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 658,440 shares of the company's stock in a transaction on Tuesday, February 24th. The stock was...

Insider Selling: Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Sells 658,440 Shares of Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 658,440 shares of the company's stock in a transaction dated Tuesday, February 24th. The stock...

Group Gp Lp Column III Sells 3,511,826 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 3,511,826 shares of the stock in a transaction on Wednesday, February 25th. The shares were...

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. Its programs include TN-201, TN-401, and TN-301. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Newell Olson in 2016 and is headquartered in South San Francisco, CA.

TNYA
Tenaya Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNYA News

TNYATenaya Therapeutics Inc